BLS Pharmaceuticals Limited · ASX:BLS
BLS Pharmaceuticals — Bioxyne — Investor Presentation (May 2024)
18 slides from BLS Pharmaceuticals's investor presentation, May 2024
Slide 1: Company Presentation
www.bioxyne.com 2024 Company Presentation Redefining Medicine for a Healthier Tomorrow BXN:ASX ODC Import License No. 2323395 ODC Export License No. 2323396 GMP Certificate No. MI-2022-LI-10650-1 QLD Health Wholesale Licence No. MWL010291721
Slide 2: Disclaimer
Bioxyne | 2024 Company Presentation 02 Disclaimer This presentation (Presentation) has been prepared by Bioxyne Limited ABN 97 084 464 193 (Bioxyne or the Company). The information in this Presentation is of a general background nature, is in summary form and does not purport to be complete. The inf
Slide 3: Table of Contents
Bioxyne | 2024 Company Presentation 03 Table of Contents 02 Disclaimer 03 Table of Contents 04 Executive Summary 05 Key Company Highlights 10 06 Our Approach to Medicine 07 Measuring Our Impact 08 Global Leadership Team 09 Company Structure Vision 04 10 Vision 11 Charts 07 17 2023 year in review Mea
Slide 4: Executive Summary
Bioxyne | 2024 Company Presentation 04 Executive Summary Bioxyne (BXN:ASX), publicly traded on the Australian Stock Exchange, is a high growth, life sciences company building a stable of healthcare winners: Brands and businesses focusing on nascent markets such as plant based foods, final dose form
Slide 5: Key Company Highlights
Bioxyne | 2024 Company Presentation 05 Key Company Highlights “2023 was a huge year for the BXN group in which we showed strong growth, market-leading compliance and progress within new government regulations. We are well positioned to continue our successes through 2024 and beyond” Jason Hine COO W
Slide 6: Our Approach to Medicine
Bioxyne | 2024 Company Presentation 06 Our approach to medicine is broader than prescription only We approach health before, during, and after disease “From what we eat, the supplements we take, to the alternative & psychoactive medicines we manufacture... We are building an edifice of health, produ
Slide 7: Measuring BXN's Impact in the Global Community: Case Studies
Bioxyne | 2024 Company Presentation 07 Measuring BXN’s Impact in the Global Community: Case Studies Via its Dr Watson brand the BLS group have been engaged in the Midori-no-wa (Green Circle) Japanese joint observational study focusing on providing cost-effective CBD medication to children with intra
Slide 8: Global Leadership Team
Bioxyne | 2024 Company Presentation 08 Global Leadership Team Sam Watson Jason Hine Tony Ho Guy Robertson CEO COO Chairman CFO Damian Wood Macdarragh O’Neill Jason Stephens Samantha Bell Naotaka Tei HOQ (GMP) HOP (GMP) Director B.D. DHoP (GMP) MD Japan Stephanie Cowan Gina Koukava Alex Wilkinson Gav
Slide 9: Company Structure & Overview (2024 Outlook)
Bioxyne | 2024 Company Presentation 09 From plant based food health and wellness to mind altering pharmaceuticals Company Structure & Overview (2024 Outlook) Online, Retail, Wholesale of prescription & consumer GMP & pre pharma manufacturing of finished health products, from medical cannabis, mushro
Slide 10: BXN Vision
Bioxyne | 2024 Company Presentation 10 BXN Vision To Build a Stable of Healthcare Winners & a Global Leader in Novel Medicines. Focusing on psychoactive, psychedelic medicines, consumer health products, and plant based. Our plans for growth are focused on GMP manufacturing, sales and distribution of
Slide 11: Revenue % of Total by Business Segment Forecast 2024
Bioxyne | 2024 Company Presentation 11 Revenue % of Total by Business Segment Forecast 2024 Our growth and fiscal prudence is driven by 3 key segments of our business: 1. Sales & distribution of Dr Watson products (prescription and OTC) in Australia, UK, EU, Japan. 2. High margin manufacture of fina
Slide 12: BLS Special Medicines & Drug Development Pipeline
Bioxyne | 2024 Company Presentation 12 BLS Special Medicines & Drug Development Pipeline 2023 Launch Dr Watson Cannabis / Specials & BLS API and Starting Materials in Australia In 2023 we brought to market a dozen branded medical cannabis products in Australia working with a group of authorized pres
Slide 13: The Importance of Psychedelics & Mental Health
Bioxyne | 2024 Company Presentation 13 The Importance of Psychedelics & Mental Health Over 300 million people globally experience symptoms of depression.1 Mood disorders, including depression, are significant predictors of suicide and suicidal ideation and are responsible for over 800 000 global sui
Slide 14: The Importance of Medical Cannabis as a Potential Substitute for Opioids
Bioxyne | 2024 Company Presentation 14 The Importance of medical cannabis as a potential substitute for opioids & increasing patient access Surveillance studies from countries that have approved the use of Sativex, which is a cannabis-based product, have demonstrated that a combination of Δ9-tetrahy
Slide 15: Forecasted Global Legal Cannabis Market Size, 2024
Bioxyne | 2024 Company Presentation 15 Forecasted Global Legal Cannabis Market Size, 2024 (US$) EUROPE NORTH AMERICA AND CANADA 39.1B ASIA 37.9B 12.5B AFRICA LATAM AND 2.6B OCEANIA 2.7B THE CARIBBEAN 9.1B TOTAL 103.9B
Slide 16: Comparable Companies
Bioxyne | 2024 Company Presentation 16 Comparable Companies Company Name Revenue & Net Income Share Price Market Capitalization Mkt Cap / Revenue (Loss) ’21 or LTM (TTM) ATAI LIFE SCIENCES (NASDAQ:ATAI) US$20M & ($210M) $3.69 US$593M 29.7x COMPASS PATHWAYS (NASDAQ:CMPS) US$0 & ($71M) $9.24 US$393M ∞
Slide 17: Looking Back on 2023
Bioxyne | 2024 Company Presentation 17 Looking Back on 2023 BLS developing interventional study BLS has been granted BXN:ASX completes BLS signs deal with CanXchange of psilocybin-assisted Australia’s first GMP acquisition of Breathe to launch B2B medical cannabis therapy in cancer licence to manufa
Slide 18: Bioxyne | 2024 Company Presentation
Bioxyne | 2024 Company Presentation 18